Description
Using O-glycan biomarkers, a vaccine against Covid-19 virus will be confirmed as non-toxic and then tested at the clinical level (phase I).
Amendment chain · 8 entries
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header. For this agreement: $3,978,832 at start, $8,477,787 after amendment #10 (+$4,498,955).
- #02020-08-31$3,978,832
- #42021-08-26$5,552,600+$1,573,768
- #52022-02-21$5,612,600+$60,000
- #62022-07-14$5,612,600
- #72022-10-06$8,102,787+$2,490,187
- #82023-03-28$8,102,787
- #92023-12-11$8,102,787
- #102024-03-28$8,477,787+$375,000
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2020-08-31(start date) | $3,978,832 | — | Using O-glycan biomarkers, a vaccine against Covid-19 virus will be confirmed as non-toxic and then tested at… |
| #4 amendment | 2021-08-26 | $5,552,600 | +$1,573,768 | Using O-glycan biomarkers, a vaccine against Covid-19 virus will be confirmed as non-toxic and then tested at… |
| #5 amendment | 2022-02-21 | $5,612,600 | +$60,000 | Using O-glycan biomarkers, a vaccine against Covid-19 virus will be confirmed as non-toxic and then tested at… |
| #6 amendment | 2022-07-14 | $5,612,600 | +$0 | Using O-glycan biomarkers, a vaccine against Covid-19 virus will be confirmed as non-toxic and then tested at… |
| #7 amendment | 2022-10-06 | $8,102,787 | +$2,490,187 | Using O-glycan biomarkers, a vaccine against Covid-19 virus will be confirmed as non-toxic and then tested at… |
| #8 amendment | 2023-03-28 | $8,102,787 | +$0 | Using O-glycan biomarkers, a vaccine against Covid-19 virus will be confirmed as non-toxic and then tested at… |
| #9 amendment | 2023-12-11 | $8,102,787 | +$0 | Using O-glycan biomarkers, a vaccine against Covid-19 virus will be confirmed as non-toxic and then tested at… |
| #10 amendment | 2024-03-28 | $8,477,787 | +$375,000 | Using O-glycan biomarkers, a vaccine against Covid-19 virus will be confirmed as non-toxic and then tested at… |
Related records · 7
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (business number 747665529)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 093-2024-2025-Q2-00012 | Canada Economic Development for Quebec Regions | Développement économique Canada pour les régions du Québec · The Regional Economic Growth Through Innovation Program (REGI) | $250,000 | FY2025 |
| 172-2018-2019-Q1-905044 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Contributions to Firms | $50,000 | FY2019 |
Other recipients funded under "Industrial Research Assistance Program – Contributions to Firms" by National Research Council Canada | Conseil national de recherches Canada (most recent first)
| Ref | Recipient | Fiscal year | Current value | FY |
|---|---|---|---|---|
| 172-2025-2026-Q2-1034675 | Mediphage Bioceuticals, Inc. | FY2027 | $63,380 | FY2027 |
| 172-2025-2026-Q3-1037522 | OBKIO INC. | FY2026 | $50,000 | FY2026 |
| 172-2025-2026-Q3-1037889 | SERVICES DE DEVELOPPEMENT PROFESSIONELS SDP INC | FY2026 | $25,000 | FY2026 |
| 172-2025-2026-Q2-1034040 | Griffith Foods Limited | FY2026 | $54,880 | FY2026 |
| 172-2025-2026-Q3-1037273 | Apollo Machine & Welding Ltd. | FY2026 | $230,000 | FY2026 |
Cite as: Glassbox record view · Federal grants & contributions · 172-2020-2021-Q2-957295 · retrieved 2026-11-15.